Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
59,964,750
-
Total 13F shares
-
52,975,330
-
Share change
-
+756,209
-
Total reported value
-
$1,383,751,451
-
Put/Call ratio
-
92%
-
Price per share
-
$26.13
-
Number of holders
-
178
-
Value change
-
+$26,879,081
-
Number of buys
-
101
-
Number of sells
-
80
Institutional Holders of Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) as of Q4 2018
As of 31 Dec 2018,
Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) was held by
178 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
52,975,330 shares.
The largest 10 holders included
BlackRock Inc., Consonance Capital Management LP, Vanguard Group Inc, Palo Alto Investors LP, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, MACQUARIE GROUP LTD, ADAGE CAPITAL PARTNERS GP, L.L.C., GLENMEDE TRUST CO NA, and FMR LLC.
This page lists
178
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.